Induction of the drug metabolizing enzyme CYP2D in monkey brain by chronic nicotine treatment

Neuropharmacology

Volumn 55, Issue 7, 2008, Pages 1147-1155

  Mann, Amandeep ^a   Miksys, Sharon ^a   Lee, Anna ^a   Mash, Deborah C ^b   Tyndale, Rachel F ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Brain drug metabolism; CYP2D6; Nicotine; Non human primate; Parkinson's disease; Smoking

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ANTIDEPRESSANT AGENT; CATECHOLAMINE; CYTOCHROME P450 2D; CYTOCHROME P450 2D6; NEUROLEPTIC AGENT; NEUROTOXIN; NICOTINE; OPIATE; PESTICIDE; SODIUM CHLORIDE;

ADOLESCENT; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN STEM; CAUDATE NUCLEUS; CERCOPITHECIDAE; CEREBELLUM; CIGARETTE SMOKING; CONTROLLED STUDY; DRUG METABOLISM; ENZYME INDUCTION; FRONTAL CORTEX; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUTAMEN; SUBSTANTIA NIGRA; WESTERN BLOTTING;

ANIMALS; BRAIN; CERCOPITHECUS AETHIOPS; CEREBELLUM; CYTOCHROME P-450 CYP2D6; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; NICOTINE; NICOTINIC AGONISTS; PHARMACEUTICAL PREPARATIONS; STEROIDS;

EID: 54049130764     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2008.07.017     Document Type: Article

References (44)

1. Alves G., Kurz M., Lie S.A., and Larsen J.P. Cigarette smoking in Parkinson's disease: influence on disease progression. Mov. Disord. 19 (2004) 1087-1092
2. Benowitz N.L., and Jacob III P. Daily intake of nicotine during cigarette smoking. Clin. Pharmacol. Ther. 35 (1984) 499-504
3. Britto M.R., and Wedlund P.J. Cytochrome P-450 in the brain. Potential evolutionary and therapeutic relevance of localization of drug-metabolizing enzymes. Drug Metab. Dispos. 20 (1992) 446-450
4. Chen Z.R., Irvine R.J., Bochner F., and Somogyi A.A. Morphine formation from codeine in rat brain: a possible mechanism of codeine analgesia. Life Sci. 46 (1990) 1067-1074
5. Coleman T., Ellis S.W., Martin I.J., Lennard M.S., and Tucker G.T. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4 - implications for susceptibility to Parkinson's disease. J. Pharmacol. Exp. Ther. 277 (1996) 685-690
6. Cribb A., Nuss C., and Wang R. Antipeptide antibodies against overlapping sequences differentially inhibit human CYP2D6. Drug Metab. Dispos. 23 (1995) 671-675
7. Edwards R.J., Price R.J., Watts P.S., Renwick A.B., Tredger J.M., Boobis A.R., and Lake B.G. Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab. Dispos. 31 (2003) 282-288
8. Elbaz A., Levecque C., Clavel J., Vidal J.S., Richard F., Amouyel P., Alperovitch A., Chartier-Harlin M.C., and Tzourio C. CYP2D6 polymorphism, pesticide exposure, and Parkinson's disease. Ann. Neurol. 55 (2004) 430-434
9. Funck-Brentano C., Boelle P.Y., Verstuyft C., Bornert C., Becquemont L., and Poirier J.M. Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects. Eur. J. Clin. Pharmacol. 61 (2005) 821-829
10. Herraiz T., Guillen H., Aran V.J., Idle J.R., and Gonzalez F.J. Comparative aromatic hydroxylation and N-demethylation of MPTP neurotoxin and its analogs, N-methylated beta-carboline and isoquinoline alkaloids, by human cytochrome P450 2D6. Toxicol. Appl. Pharmacol. 216 (2006) 387-398
11. Howard L.A., Miksys S., Hoffmann E., Mash D., and Tyndale R.F. Brain CYP2E1 is induced by nicotine and ethanol in rat and is higher in smokers and alcoholics. Br. J. Pharmacol. 138 (2003) 1376-1386
12. Jimenez-Jimenez F.J., Tabernero C., Mena M.A., Garcia de Yebenes J., Garcia de Yebenes M.J., Casarejos M.J., Pardo B., Garcia-Agundez J.A., Benitez J., Martinez A., et al. Acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in a model of rat designated a poor metabolizer of debrisoquine. J. Neurochem. 57 (1991) 81-87
13. Joshi M., and Tyndale R.F. Regional and cellular distribution of CYP2E1 in monkey brain and its induction by chronic nicotine. Neuropharmacology 50 (2006) 568-575
14. Kawashima H., Sequeira D.J., Nelson D.R., and Strobel H.W. Genomic cloning and protein expression of a novel rat brain cytochrome P-450 CYP2D18* catalyzing imipramine N-demethylation. J. Biol. Chem. 271 (1996) 28176-28180
15. Lee A.M., Miksys S., Palmour R., and Tyndale R.F. CYP2B6 is expressed in African Green monkey brain and is induced by chronic nicotine treatment. Neuropharmacology 50 (2006) 441-450
16. Martin R.F., and Bowden D.M. Primate Brain Maps: Structure of the Macaque Brain: A Laboratory Guide with Original Brain Sections (2000), Amsterdam, Oxford: Elsevier (Printed atlas and electronic templates for data and schematics by Richard F. Martin and Douglas M. Bowden; software by John Wu, Mark F. Dubach and Joan E. Robertson).
17. Matoh N., Tanaka S., Takehashi M., Banasik M., Stedeford T., Masliah E., Suzuki S., Nishimura Y., and Ueda K. Overexpression of CYP2D6 attenuates the toxicity of MPP+ in actively dividing and differentiated PC12 cells. Gene Expr. 11 (2003) 117-124
18. McCann S.J., Pond S.M., James K.M., and Le Couteur D.G. The association between polymorphisms in the cytochrome P-450 2D6 gene and Parkinson's disease: a case-control study and meta-analysis. J. Neurol. Sci. 153 (1997) 50-53
19. Michels R., and Marzuk P.M. Progress in psychiatry (1). N. Engl. J. Med. 329 (1993) 552-560
20. Miksys S., Rao Y., Hoffmann E., Mash D.C., and Tyndale R.F. Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics. J. Neurochem. 82 (2002) 1376-1387
21. Miksys S., Rao Y., Sellers E.M., Kwan M., Mendis D., and Tyndale R.F. Regional and cellular distribution of CYP2D subfamily members in rat brain. Xenobiotica 30 (2000) 547-564
22. Nakayama H., Okuda H., Nakashima T., Imaoka S., and Funae Y. Nicotine metabolism by rat hepatic cytochrome P450s. Biochem. Pharmacol. 45 12 (1993) 2554-2556
23. Ng P.S., Imaoka S., Hiroi T., Osada M., Niwa T., Kamataki T., and Funae Y. Production of inhibitory polyclonal antibodies against cytochrome P450s. Drug Metab. Pharmacokinet. 18 (2003) 163-172
24. Norris P.J., Hardwick J.P., and Emson P.C. Regional distribution of cytochrome P450 2D1 in the rat central nervous system. J. Comp. Neurol. 366 (1996) 244-258
25. Quik M., Chen L., Parameswaran N., Xie X., Langston J.W., and McCallum S.E. Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates. J. Neurosci. 26 (2006) 4681-4689
26. Quik M., Parameswaran N., McCallum S.E., Bordia T., Bao S., McCormack A., Kim A., Tyndale R.F., Langston J.W., and Di Monte D.A. Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates. J. Neurochem. 98 (2006) 1866-1875
27. Quik M., Cox H., Parameswaran N., O'Leary K., Langston J.W., and Di Monte D. Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys. Ann. Neurol. (2007)
28. Rae J.M., Johnson M.D., Lippman M.E., and Flockhart D.A. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J. Pharmacol. Exp. Ther. 299 (2001) 849-857
29. Riedl A.G., Watts P.M., Edwards R.J., Boobis A.R., Jenner P., and Marsden C.D. Selective localisation of P450 enzymes and NADPH-P450 oxidoreductase in rat basal ganglia using anti-peptide antisera. Brain Res. 743 (1996) 324-328
30. Riedl A.G., Watts P.M., Edwards R.J., Schulz-Utermoehl T., Boobis A.R., Jenner P., and Marsden C.D. Expression and localisation of CYP2D enzymes in rat basal ganglia. Brain Res. 822 (1999) 175-191
31. Schneider N.G., Olmstead R.E., Franzon M.A., and Lunell E. The nicotine inhaler: clinical pharmacokinetics and comparison with other nicotine treatments. Clin. Pharmacokinet. 40 (2001) 661-684
32. Schoedel K.A., Sellers E.M., Palmour R., and Tyndale R.F. Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration. Mol. Pharmacol. 63 (2003) 96-104
33. Siegle I., Fritz P., Eckhardt K., Zanger U.M., and Eichelbaum M. Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics 11 (2001) 237-245
34. Snider R.S., and Lee J.C. A Sterotaxic Atlas of the Monkey Brain (Macaca mulatta) (1961), University Press, Chicago
35. Suzuki T., Fujita S., Narimatsu S., Masubuchi Y., Tachibana M., Ohta S., and Hirobe M. Cytochrome P450 isozymes catalyzing 4-hydroxylation of Parkinsonism-related compound 1,2,3,4-tetrahydroisoquinoline in rat liver microsomes. Faseb J. 6 (1992) 771-776
36. Tang J., Cao Y., Rose R.L., and Hodgson E. In vitro metabolism of carbaryl by human cytochrome P450 and its inhibition by chlorpyrifos. Chem. Biol. Interact. 141 (2002) 229-241
37. Tyndale R.F., Sunahara R., Inaba T., Kalow W., Gonzalez F.J., and Niznik H.B. Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. Mol. Pharmacol. 40 (1991) 63-68
38. Tyndale R.F., Li Y., Li N.Y., Messina E., Miksys S., and Sellers E.M. Characterization of cytochrome P-450 2D1 activity in rat brain: high-affinity kinetics for dextromethorphan. Drug Metab. Dispos. 27 (1999) 924-930
39. Vaglini F., Pardini C., Viaggi C., Bartoli C., Dinucci D., and Corsini G.U. Involvement of cytochrome P450 2E1 in the 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease. J. Neurochem. 91 2 (2004) 285-298
40. Voirol P., Jonzier-Perey M., Porchet F., Reymond M.J., Janzer R.C., Bouras C., Strobel H.W., Kosel M., Eap C.B., and Baumann P. Cytochrome P-450 activities in human and rat brain microsomes. Brain Res. 855 (2000) 235-243
41. Watts P.M., Riedl A.G., Douek D.C., Edwards R.J., Boobis A.R., Jenner P., and Marsden C.D. Co-localization of P450 enzymes in the rat substantia nigra with tyrosine hydroxylase. Neuroscience 86 (1998) 511-519
42. Yu A.M., Idle J.R., Krausz K.W., Kupfer A., and Gonzalez F.J. Contribution of individual cytochrome P450 isozymes to the O-demethylation of the psychotropic beta-carboline alkaloids harmaline and harmine. J. Pharmacol. Exp. Ther. 305 (2003) 315-322
43. Yue J., Miksys S., Hoffmann E., and Tyndale R.F. Chronic nicotine treatment induces rat CYP2D in the brain but not in the liver: an investigation of induction and time course. J. Psychiatry Neurosci. 33 (2008) 54-63
44. Zanger U.M., Raimundo S., and Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch. Pharmacol. 369 (2004) 23-37